Early Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Breast Cancer Treated with Eribulin After Prior Immuno-Oncology or Antibody–Drug Conjugate Therapy

INTRODUCTION: Eribulin was approved by the FDA in 2010 for the treatment of metastatic breast cancer (MBC) in the United States (US). More recently, several immuno-oncology (IO) and antibody–drug conjugate (ADC) regimens have been approved for MBC. We assessed the treatment patterns and clinical out...

Descripción completa

Detalles Bibliográficos
Autores principales: Goyal, Ravi K, Zhang, Jingchuan, Davis, Keith L, Sluga-O’Callaghan, Martina, Kaufman, Peter A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661956/
https://www.ncbi.nlm.nih.gov/pubmed/38020049
http://dx.doi.org/10.2147/BCTT.S422025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661956/
https://www.ncbi.nlm.nih.gov/pubmed/38020049
http://dx.doi.org/10.2147/BCTT.S422025

Ejemplares similares